64Cu-daratumumab (SUVmean) uptake and background contribution of blood activity to BM uptake categorized by dose of unlabeled daratumumab
| . | 0 mg . | 10 mg . | 45 mg . | 95 mg . | ||||
|---|---|---|---|---|---|---|---|---|
| Organs . | Day 1 . | Day 2 . | Day 1 . | Day 2 . | Day 1 . | Day 2 . | Day 1 . | Day 2 . |
| BM | 14.1 ± 2.1 | 13.7 ± 1.1 | 20.9 ± 3.3 | 19.2 ± 3.1 | 34.8 ± 9.6* | 33.9 ± 11.0* | 6.4 ± 3.0 | 7.3 ± 3.8 |
| Liver | 15.5 ± 3.1 | 16.1 ± 0.6 | 11.6 ± 3.5 | 11.7 ± 4.0 | 6.1 ± 1.9 | 6.3 ± 1.9 | 5.1 ± 1.8 | 5.0 ± 1.7 |
| Spleen | 50.5 ± 19.3 | 47.2 ± 16.3 | 27.2 ± 4.0 | 23.6 ± 3.7 | 9.5 ± 2.9 | 8.6 ± 2.4 | 6.2 ± 1.4 | 5.5 ± 1.5 |
| Blood (heart) | 1.8 ± 0.6 | 1.3 ± 0.6 | 1.5 ± 0.1 | 1.5 ± 0.4 | 0.9 ± 0.3* | 0.8 ± 0.4* | 7.5 ± 0.3 | 4.6 ± 0.9 |
| Blood activity contribution to BM, % | 4.7 ± 1.6 | 3.4 ± 1.6 | 2.6 ± 0.4 | 2.9 ± 0.9 | 1.0 ± 0.4* | 0.9 ± 0.5* | 42.0 ± 19.8 | 22.7 ± 12.6 |
| . | 0 mg . | 10 mg . | 45 mg . | 95 mg . | ||||
|---|---|---|---|---|---|---|---|---|
| Organs . | Day 1 . | Day 2 . | Day 1 . | Day 2 . | Day 1 . | Day 2 . | Day 1 . | Day 2 . |
| BM | 14.1 ± 2.1 | 13.7 ± 1.1 | 20.9 ± 3.3 | 19.2 ± 3.1 | 34.8 ± 9.6* | 33.9 ± 11.0* | 6.4 ± 3.0 | 7.3 ± 3.8 |
| Liver | 15.5 ± 3.1 | 16.1 ± 0.6 | 11.6 ± 3.5 | 11.7 ± 4.0 | 6.1 ± 1.9 | 6.3 ± 1.9 | 5.1 ± 1.8 | 5.0 ± 1.7 |
| Spleen | 50.5 ± 19.3 | 47.2 ± 16.3 | 27.2 ± 4.0 | 23.6 ± 3.7 | 9.5 ± 2.9 | 8.6 ± 2.4 | 6.2 ± 1.4 | 5.5 ± 1.5 |
| Blood (heart) | 1.8 ± 0.6 | 1.3 ± 0.6 | 1.5 ± 0.1 | 1.5 ± 0.4 | 0.9 ± 0.3* | 0.8 ± 0.4* | 7.5 ± 0.3 | 4.6 ± 0.9 |
| Blood activity contribution to BM, % | 4.7 ± 1.6 | 3.4 ± 1.6 | 2.6 ± 0.4 | 2.9 ± 0.9 | 1.0 ± 0.4* | 0.9 ± 0.5* | 42.0 ± 19.8 | 22.7 ± 12.6 |
Average of the 2 newly diagnosed MM patients (patient 7 and patient 8).